The pharmacokinetics and pharmacodynamics of zaleplon delivered as a thermally generated aerosol in a single breath to volunteers

Journal of Clinical Pharmacology

Volumn 53, Issue 2, 2013, Pages 140-150

  Avram, Michael J ^a   Spyker, Daniel A ^b   Kehne, John H ^c   Cassella, James V ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Alexza Pharmaceuticals   (United States)

^c Translational Neuropharmacology Consulting   (United States)

Author keywords

Hypnotic; Inhalational delivery; Pharmacodynamics; Pharmacokinetics; Zaleplon

Indexed keywords

PLACEBO; ZALEPLON;

ADULT; AEROSOL; AREA UNDER THE CURVE; ARTICLE; BREATHING; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; EUPHORIA; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL DISORDER;

ACETAMIDES; ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AEROSOLS; AREA UNDER CURVE; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRIMIDINES; YOUNG ADULT;

EID: 84877854945     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270012436886     Document Type: Article

References (23)

1. Roth T. New developments for treating sleep disorders. J Clin Psychiatry . 2001;62(suppl 10):3-4.
2. Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clin Cornerstone . 2003;5:5-15.
3. National Institutes of Health. State of the Science Conference statement on manifestations and management of chronic insomnia in adults. Sleep . 2005;28:1049-1057.
4. National Sleep Foundation. Sleep in America, Poll 1-43 . Arlington, VA: National Sleep Foundation; 2002.
5. Hohagen F, Kappler C, Schramm E, Riemann D, Weyerer S, Berger M. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening-temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep . 1994;17:551-554.
6. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey, I. Sleep . 1999;22(suppl 2):S347-S353.
7. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol . 2004;19:305-322.
8. Walsh JK, Pollak CP, Scharf MB, Schweitzer PK, Vogel GW. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol . 2000;23:17-21.
9. Drover D, Lemmens H, Naidu S, Cevallos W, Darwish M, Stanski D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther . 2000;22:1443-1461.
10. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther . 1998;64:553-561.
11. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs . 2000;60:413-445.
12. Zaleplon capsule [package insert]. Columbus, OHL Roxane Laboratories, Inc; 2010.
13. Avram MJ, Spyker DA, Henthorn TK, Cassella JV. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther . 2009;85:71-77.
14. Sheiner BL, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters, II: biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm . 1981; 9:635-651.
15. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn . 2003;30:387-404.
16. Avram MJ, Henthorn TK, Spyker DA, et al. Recirculatory pharmacokinetic model of the uptake, distribution, and bioavailability of prochlorperazine administered as a thermally generated aerosol in a single breath to dogs. Drug Metab Dispos . 2007;35: 262-267.
17. Cobelli C, Foster DM. Compartmental models: theory and practice using the SAAM II software system. Adv Exp Med Biol . 1998;445:79-101.
18. Foster DM. Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. Adv Exp Med Biol . 1998;445:59-78.
19. Romberg R, Olofsen E, Sarton E, Teppema L, Dahan A. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology . 2003;99:788-798.
20. Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry . 2011;72:1313-1321.
21. Rosen AS, Fournie P, Darwish M, Danjou P, Troy SM. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos . 1999;20:171-175.
22. Ebling WF, Danhof M, Stanski DR. Pharmacodynamic characterization of the electroencephalographic effects of thiopental in rats. J Pharmacokinet Biopharm . 1991;19:123-143.
23. Buhrer M, Maitre PO, Hung OR, Ebling WF, Shafer SL, Stanski DR. Thiopental pharmacodynamics, I: defining the pseudo-steadystate serum concentration-EEG effect relationship. Anesthesiology . 1992;77:226-236.